2025-10-11 - Analysis Report
Okay, here's the analysis of Recursion Pharmaceuticals (RXRX), presented as a concise report.

**Recursion Pharmaceuticals Inc. (RXRX) Analysis**

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering.

**1. Performance vs. S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -14.27%
*   **VOO Cumulative Return:** 41.07%
*   **Divergence:**
    *   Current: -44.4
    *   Relative Divergence: 13.4 (Indicates RXRX is performing in the lower range of its historical divergence from VOO)

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta  | Cap (B) |
|------------|---------|-------|--------|-------|---------|
| 2021-2023  | 22.0%   | 81.0% | 26.0%  | -0.2  | 4.3     |
| 2022-2024  | 11.0%   | 81.0% | -10.0% | 0.1   | 3.0     |
| 2023-2025  | 28.0%   | 80.0% | -35.0% | 0.1   | 2.3     |

*   **Analysis:** The Alpha/Beta analysis reveals mixed performance. In the period of 2021-2023, the stock shows high alpha and negative beta. However, recent periods (2022-2025) shows decreased alpha and increase beta. CAGR remains high while MDD remains high, showing high volatility and risk.

**2. Recent Price Action**

*   **Current Price:** 5.37
*   **Last Market Data:** Price: 5.3693, Previous Close: 5.91, Change: -9.15%
*   **Moving Averages:**
    *   5-day: 5.542
    *   20-day: 5.0612
    *   60-day: 5.2682

*   **Analysis:** The stock has recently experienced a significant negative change (-9.15%). The price is below the 5-day moving average but above the 20-day and 60-day moving averages, suggesting a potential short-term downward trend but a longer-term support level.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 57.03
*   **PPO:** 1.82
*   **Hybrid Signal:** Buy 100% of cash
*   **Recent Relative Divergence Change (20-day):** 9.7 (+) - Short-term increase
*   **Expected Return:** -27.7% (vs. S&P 500)

*   **Analysis:** The MRI suggests a relatively high investment recommendation. RSI near 50 indicates neutral. Recent increased divergence indicates upward momemtum. However, negative expected return indicates that stock performance can not perform S&P 500.

**4. Recent News & Events**

*   **Positive Catalysts:** Multiple articles highlighting potential gains, renewed interest in biotech AI, and reiteration of a "Buy" rating by Needham.
*   **Negative Signals:**  One article notes RXRX dipping more than the broader market.

**4-2. Analyst Opinions**

*   **Consensus:** Hold (Mean: 2.62)
*   **Target Price:**
    *   Average: 6.47
    *   High: 10.00
    *   Low: 3.00
*   **Analysis:** Analysts' consensus is "Hold," with a wide range of target prices, indicating uncertainty about the stock's future performance.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue   |
|------------|-------|-----------|
| 2025-08-05 | -0.41 | 0.02 B$  |
| 2025-05-05 | -0.5  | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2024-08-08 | -0.4  | 0.01 B$  |
| 2025-08-05 | -0.4  | 0.01 B$  |

*   **Analysis:** The company has consistently reported negative EPS. Revenue has fluctuated slightly.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | \$0.02B    | -5.54%        |
| 2025-03-31 | \$0.01B    | -47.31%       |
| 2024-12-31 | \$0.00B    | -183.62%      |
| 2024-09-30 | \$0.03B    | 53.69%        |
| 2024-06-30 | \$0.01B    | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE       |
|------------|------------|-----------|
| 2025-06-30 | \$0.92B    | -18.70%   |
| 2025-03-31 | \$0.93B    | -21.68%   |
| 2024-12-31 | \$1.03B    | -17.29%   |
| 2024-09-30 | \$0.52B    | -18.27%   |
| 2024-06-30 | \$0.58B    | -16.69%   |

*   **Analysis:** Revenue is relatively low and inconsistent. Profit margins have been volatile, with some quarters showing positive margins but most being negative. ROE is consistently negative, indicating the company is not generating profits from its equity.

**7. Overall Assessment**

RXRX presents a mixed investment profile. The company operates in the promising field of AI-driven drug discovery, and recent news suggests potential positive catalysts. However, the stock has underperformed the S&P 500 significantly, and financial metrics (negative EPS, inconsistent revenue, negative ROE) raise concerns. Analyst opinions are mixed, and the recent price drop adds to the uncertainty. The Market Risk Indicator is relatively high. While the Hybrid Signal says Buy, the negative expected return is concerning.

**Recommendation:** Given the high risk and uncertain financial outlook, a cautious approach is warranted. Investors should carefully weigh the potential upside against the significant risks before considering an investment in RXRX.
